Healthcare Reimagined

September 5, 2020

The first attempt to quantify glucose in urine was made in the 1800s. It was commercialised in 1908 and later became the only method to quantify glucose for the next 50 years until the blood glucose test strip was introduced. Today, the blood glucose test strip is still the most used method all around the world, even after over 50 years since its invention.

In 1999 the continuous glucose monitor (CGM), a wearable device, was approved by the FDA. However it was not successful commercially as it caused skin irritation despite the sensor being labelled as technologically non-invasive.

Although glucose monitoring technology continues to improve—eg. smaller amounts of blood required for testing, the development of electrochemical strips, the discovery of new enzymatic tests, upgraded lancets, etc.—there have been no new game changing technologies that can be readily commercialised. The lack of balance between available technology with cost-effectiveness and accuracy becomes the deterrent for change.

Glucosenz is ready to disrupt the current market by being the first non-invasive glucose monitoring device that can be commercialised and widely used as it is technologically ready, cost-effective and involves no pain (no pricking and no blood).

The use of Glucosenz, which features NIR lightsource technology, in medical institutions, clinics or at home will remove the need for consumables (used in current testing methods) such as needles, strips, and alcohol swabs, thereby significantly lowering medical waste management costs and making waste disposal procedures simpler and safer.